Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Get Rating) have earned a consensus rating of "Moderate Buy" from the eleven research firms that are presently covering the stock, Marketbeat Ratings reports. Three research analysts have rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $59.22.
Several research firms recently commented on ARWR. SVB Leerink cut their price target on Arrowhead Pharmaceuticals from $33.00 to $31.00 and set a "market perform" rating on the stock in a research note on Tuesday, November 29th. Chardan Capital cut their price target on Arrowhead Pharmaceuticals from $82.00 to $60.00 in a research note on Tuesday, January 10th. Piper Sandler cut their price target on Arrowhead Pharmaceuticals from $64.00 to $55.00 in a research note on Monday, January 9th. The Goldman Sachs Group reiterated a "buy" rating and issued a $66.00 price target (up previously from $65.00) on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, November 30th. Finally, Jefferies Financial Group cut their price target on Arrowhead Pharmaceuticals from $92.00 to $75.00 and set a "buy" rating on the stock in a research note on Tuesday, November 29th.
Get Arrowhead Pharmaceuticals alerts:Insider Buying and Selling at Arrowhead Pharmaceuticals
In other Arrowhead Pharmaceuticals news, Director William D. Waddill sold 3,200 shares of the company's stock in a transaction that occurred on Monday, January 9th. The stock was sold at an average price of $30.00, for a total transaction of $96,000.00. Following the sale, the director now owns 28,950 shares in the company, valued at $868,500. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other news, Director William D. Waddill sold 3,200 shares of the stock in a transaction that occurred on Monday, January 9th. The stock was sold at an average price of $30.00, for a total transaction of $96,000.00. Following the sale, the director now directly owns 28,950 shares in the company, valued at approximately $868,500. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Martin Javier San sold 19,500 shares of the stock in a transaction that occurred on Monday, November 21st. The stock was sold at an average price of $29.99, for a total value of $584,805.00. Following the sale, the insider now owns 91,500 shares in the company, valued at $2,744,085. The disclosure for this sale can be found here. Insiders have sold 109,966 shares of company stock worth $4,050,435 over the last quarter. 3.20% of the stock is owned by corporate insiders.
Institutional Trading of Arrowhead Pharmaceuticals
Institutional investors and hedge funds have recently made changes to their positions in the stock. Captrust Financial Advisors grew its holdings in Arrowhead Pharmaceuticals by 22.4% in the 2nd quarter. Captrust Financial Advisors now owns 1,201 shares of the biotechnology company's stock worth $42,000 after buying an additional 220 shares in the last quarter. Arizona State Retirement System grew its holdings in Arrowhead Pharmaceuticals by 1.2% in the 2nd quarter. Arizona State Retirement System now owns 27,151 shares of the biotechnology company's stock worth $956,000 after buying an additional 309 shares in the last quarter. Private Advisor Group LLC grew its holdings in Arrowhead Pharmaceuticals by 2.7% in the 3rd quarter. Private Advisor Group LLC now owns 11,795 shares of the biotechnology company's stock worth $390,000 after buying an additional 313 shares in the last quarter. O Shaughnessy Asset Management LLC grew its holdings in Arrowhead Pharmaceuticals by 3.5% in the 2nd quarter. O Shaughnessy Asset Management LLC now owns 9,704 shares of the biotechnology company's stock worth $342,000 after buying an additional 326 shares in the last quarter. Finally, State of Alaska Department of Revenue grew its holdings in Arrowhead Pharmaceuticals by 2.2% in the 2nd quarter. State of Alaska Department of Revenue now owns 15,173 shares of the biotechnology company's stock worth $534,000 after buying an additional 330 shares in the last quarter. 65.46% of the stock is currently owned by institutional investors and hedge funds.Arrowhead Pharmaceuticals Price Performance
Shares of NASDAQ ARWR opened at $36.82 on Tuesday. Arrowhead Pharmaceuticals has a 1-year low of $26.81 and a 1-year high of $58.96. The business has a 50-day moving average of $33.74 and a 200-day moving average of $36.71. The company has a market capitalization of $3.90 billion, a price-to-earnings ratio of -21.92 and a beta of 1.26.
Arrowhead Pharmaceuticals (NASDAQ:ARWR – Get Rating) last issued its earnings results on Monday, November 28th. The biotechnology company reported ($0.81) earnings per share for the quarter, missing the consensus estimate of ($0.57) by ($0.24). Arrowhead Pharmaceuticals had a negative return on equity of 40.23% and a negative net margin of 71.01%. The company had revenue of $31.58 million during the quarter, compared to analysts' expectations of $107.60 million. Research analysts expect that Arrowhead Pharmaceuticals will post -0.59 EPS for the current fiscal year.
About Arrowhead Pharmaceuticals
(Get Rating)
Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in phase 2b clinical trial for the treatment of dyslipidemia; ARO-HSD, which is completed phase 1/2 clinical trial to treat liver diseases; ARO-ENaC2, which is in pre-clinical stage for the treatment of dyslipidemia cystic fibrosis; ARO-C3 that is in phase 1/2a clinical trial to reduce production of complement component 3; ARO-DUX4, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH that is in phase 1 clinical trial to treat uncontrolled gout; ARO-COV, which is in pre-clinical stage for the treatment of COVID-19; ARO-RAGE, which is in phase 1/2a clinical trial to treat muco-obstructive or inflammatory pulmonary conditions; and ARO-MMP7 that is in phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis.
See Also
- Get a free copy of the StockNews.com research report on Arrowhead Pharmaceuticals (ARWR)
- Why Warner Bros Discovery Is the S&P's Hottest Stock
- Is Walgreens Boots Alliance Earnings Miss Good For Investors?
- Pinterest is the Social Commerce Platform to Watch in 2023
- 4 High-Yield Dividend Kings For 2023
- Will 2023 be a Good Year for Goodyear Tire Stock?
Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.